Ad
related to: alcohol septal ablation treatment
Search results
Results from the WOW.Com Content Network
Alcohol septal ablation (ASA) is a minimally invasive heart procedure to treat hypertrophic cardiomyopathy (HCM). [1]It is a percutaneous, minimally invasive procedure performed by an interventional cardiologist to relieve symptoms and improve functional status in eligible patients with severely symptomatic HCM who meet strict clinical, anatomic and physiologic selection criteria.
The device fastens together the mitral valve leaflets to improve the heart's blood outflow. The mitral clip has not yet established the same long-term reliability as septal myectomy or alcohol septal ablation, but HCM specialists are increasingly offering the clip as a less-invasive treatment option. [60] [61]
Ordinarily, septal myectomies are performed only after attempts at treatment with medication fail. The choice between septal myectomy and alcohol ablation is a complex medical decision. [citation needed] Septal myectomy was established by Andrew G. Morrow in the 1960s. [3]
Ulrich Sigwart (German: [ˈʊlʁɪç ˈziːkvaʁt]; born 9 March 1941) is a German retired cardiologist known for his pioneering role in the conception and clinical use of stents to keep blood vessels open, and introducing a non-surgical intervention, alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy.
Srihari S. Naidu is an American physician and Professor of Medicine at New York Medical College who is known for his work on hypertrophic cardiomyopathy including the procedure known as alcohol septal ablation, and for helping to construct the universal diagnostic criteria for cardiogenic shock.
What is sugar alcohol? According to Beaumont Health, sugar alcohol is a reduced-calorie sweetener. It is a carbohydrate with a chemical makeup similar to sugar — meaning it can activate ...
Not all ghost towns are from the Old West, and the reasons vary why a popular tourist destination might become abandoned. Here are 16 from Detroit to Taiwan.
Charles Knight is a British professor of cardiology and chief executive of St Bartholomew's Hospital, part of Barts Health NHS Trust.. In 1994 he assisted in the first percutaneous alcohol septal ablation, a non-surgical method for the treatment of hypertrophic obstructive cardiomyopathy as an alternative to open heart surgery, and subsequently specialised in the procedure.
Ad
related to: alcohol septal ablation treatment